Stock Taper 
APMD
$28.03
▼ DOWN 1.82% (-0.52)
KEY STATISTICS
Market Cap$1.12 B
52w High$35.29
52w Low$16.12
Dividend Yield—
Frequency—
P/E—
Volume246.33K
Shares Out.39.82M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Kevin R. Lind
ABOUT
SECTOR
Healthcare
WENT PUBLIC
July 29, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
65
PRICE
$28.03 ▼ DOWN 1.82% (−$0.52)About Apnimed, Inc.
https://apnimed.com ↗Apnimed, Inc. is a Cambridge-based clinical pharmaceutical company developing novel oral therapies, like AD109, to treat sleep-related breathing disorders such as obstructive sleep apnea by targeting neurobiological dysfunction.
INDUSTRY
Biotechnology
A PRODUCT APNIMED, INC. IS KNOWN FOR
AD109 (Oxnimbi)
AD109 (Oxnimbi) is an investigational once-daily oral drug targeting the neuromuscular cause of obstructive sleep apnea, with an FDA action date set for February 28, 2027.
